Dermatitis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Dermatitis stocks.

Dermatitis Stocks Recent News

Date Stock Title
Sep 20 REGN Regeneron/Sanofi Dupixent endorsed in EU for eosinophilic esophagitis for children
Sep 20 REGN Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
Sep 19 REGN The best biotech plays outside the GLP-1 weight-loss market
Sep 19 BHC Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Sep 19 ARQT Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
Sep 19 BHC Bausch (BHC) Surges 11.7%: Is This an Indication of Further Gains?
Sep 17 BHC Bausch Health Taps Jefferies to Refinance Debt, Aid Spinoff
Sep 17 REGN Jim Cramer Says Regeneron Pharmaceuticals Inc. (REGN)’s Oncology Portfolio is Beautiful
Sep 17 HOTH Hoth Therapeutics stock climbs on promising preclinical results for its Alzheimer's drug
Sep 17 HOTH Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
Sep 17 BHC Bausch + Lomb (BLCO) Surges 14.5%: Is This an Indication of Further Gains?
Sep 16 BHC Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?
Sep 16 BHC Why Bausch + Lomb Rallied Today
Sep 16 BHC Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues
Sep 16 REGN Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
Sep 16 BHC Bausch + Lomb Stock Jumps Amid Reports Of A Sale
Sep 16 BHC Top Midday Stories: New iPhone Sees Sluggish Demand; Boeing to Freeze Hiring, Curb Expenses; Intel Wins Defense Contract; Government Deadline to Review US Steel-Nippon Deal Nears
Sep 16 BHC Bausch + Lomb rises 13% on potential sale chatter
Sep 16 BHC Bausch + Lomb Soars on Report That It’s Exploring a Sale
Sep 16 BHC Biggest stock movers today: DJT, INTC, BLCO and more
Dermatitis

Dermatitis, also known as eczema, is a group of diseases that results in inflammation of the skin. These diseases are characterized by itchiness, red skin and a rash. In cases of short duration, there may be small blisters, while in long-term cases the skin may become thickened. The area of skin involved can vary from small to the entire body.Dermatitis is a group of skin conditions that includes atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis and stasis dermatitis. The exact cause of dermatitis is often unclear. Cases may involve a combination of irritation, allergy and poor venous return. The type of dermatitis is generally determined by the person's history and the location of the rash. For example, irritant dermatitis often occurs on the hands of people who frequently get them wet. Allergic contact dermatitis occurs upon exposure to an allergen, causing a hypersensitivity reaction in the skin.Treatment of atopic dermatitis is typically with moisturizers and steroid creams. The steroid creams should generally be of mid- to high strength and used for less than two weeks at a time as side effects can occur. Antibiotics may be required if there are signs of skin infection. Contact dermatitis is typically treated by avoiding the allergen or irritant. Antihistamines may help with sleep and to decrease nighttime scratching.Dermatitis was estimated to affect 245 million people globally in 2015. Atopic dermatitis is the most common type and generally starts in childhood. In the United States, it affects about 10–30% of people. Contact dermatitis is twice as common in females than males. Allergic contact dermatitis affects about 7% of people at some point in time. Irritant contact dermatitis is common, especially among people who do certain jobs; exact rates are unclear.

Browse All Tags